Article thumbnail

Biosimilar agents in oncology/haematology: from approval to practice

By Dietger Niederwieser and Stephan Schmitz

Abstract

The regulation of biosimilars is a process that is still developing. In Europe, guidance regarding the approval and use of biosimilars has evolved with the products under consideration. It is now more than 3 years since the first biosimilar agents in oncology support, erythropoiesis-stimulating agents, were approved in the EU. More recently, biosimilar granulocyte colony-stimulating factors have received marketing approval in Europe. This review considers general issues surrounding the introduction of biosimilars and highlights current specific issues pertinent to their use in clinical practice in oncology. Information on marketing approval, extrapolation, labelling, substitution, immunogenicity and traceability of each biosimilar product is important, especially in oncology where patients are treated in repeated therapy courses, often with complicated protocols, and where biosimilars are not used as a unique therapy for replacement of e.g. growth hormone or insulin. While future developments in the regulation of biosimilars will need to address multiple issues, in the interim physicians should remain aware of the inherent differences between biosimilar and innovator products

Topics: Review Article
Publisher: Blackwell Publishing Ltd
OAI identifier: oai:pubmedcentral.nih.gov:3085072
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. Agency. CPMP⁄QWP⁄328⁄99 -development pharmaceutics for biotechnological and biological products - Annex to Note for Guidance on Development Pharmaceutics (CPMP⁄QWP⁄155⁄96). Available from: http://www.emea.europa.eu/pdfs/human/bwp/ 032899en.pdf.
  2. Agency. Guideline on similar biological medicinal products (CHMP⁄437⁄04). Available from: http://www.emea.europa.eu/pdfs/human/biosimilar/ 043704en.pdf.
  3. Agency. Human Medicines - EMEA Procedural Advice for Users of the Centralised Procedure for Generic⁄Hybrid Applications (EMEA⁄CHMP⁄225411⁄2006). Available from:
  4. (1998). Agency. ICH Topic S6, preclinical safety evaluation of biotechnology-derived pharmaceuticals
  5. Agency. Procedures for marketing authorisation, Notice to Applicants,
  6. Agency. Questions and Answers on biosimilar medicines (similar biological medicinal products) (EMEA⁄74562⁄2006). Available from:
  7. Biologicals in the era of biosimilars: implications for naming and prescribing.
  8. (2007). Biotherapeutics in the era of biosimilars: what really matters is patient safety. Drug Saf
  9. (2008). Economic issues with follow-on protein products. Nat Rev Drug Discov
  10. Follow-on biologics: challenges of the ‘next generation’.
  11. Interpretation of the new EMEA guidelines in similar biological medicinal products.
  12. The challenge of biosimilars.
  13. The first biosimilar epoetin: but how similar is it?
  14. The protein science of biosimilars.